Acadia Pharmaceuticals | ACAD - Ingresos Por Ventas





Ventas Cambio Fecha
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
ALKERMES USD 496.01M 103.1M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Biogen USD 2.74B 490M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Bristol-Myers Squibb USD 12.97B 1.48B 2026-06
Cara Therapeutics USD 2.57M 1.11M 2025-03
Corcept Therapeutics USD 256.15M 91.25M 2026-06
Cytokinetics USD 28.6M 9.25M 2026-06
Eisai JPY 234.33B 28.9B 2026-06
Eli Lilly USD 22.97B 3.17B 2026-06
Incyte USD 1.67B 400M 2026-06
J&J USD 25.31B 1.21B 2026-06
Moderna USD 100M 289M 2026-06
Neurocrine Biosciences USD 959M 148M 2026-06
Pfizer USD 15.03B 530M 2026-06
Prothena USD 51.08M 51.06M 2026-03
PTC Therapeutics USD 361M 88M 2026-06
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 3.33B 340M 2026-06